LYELL IMMUNOPHARMA INC (LYEL)

Company Profile

Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company is headquartered in South San Francisco, California and currently employs 224 full-time employees. The company went IPO on 2021-06-17. The firm is engaged in enrolling a Phase I clinical trial evaluating a ROR1-targeted CAR T-cell therapy in patients with relapsed refractory triple-negative breast cancer and non-small cell lung cancer (NSCLC) and a second Phase I clinical trial evaluating reprogrammed tumor infiltrating lymphocytes (TIL) in patients with advanced melanoma, NSCLC and colorectal cancer. The technologies powering its product candidates are designed to address barriers that limit consistent and long-lasting responses to cell therapy for solid tumors: T-cell exhaustion and lack of durable stemness, which includes the ability to persist and self-renew to drive durable tumor cytotoxicity. The firm is applying its proprietary ex vivo genetic and epigenetic reprogramming technologies to address these barriers in order to develop medicines.

Company Info

LYELL IMMUNOPHARMA INC

201 Haskins Way, Suite 301

South San Francisco CALIFORNIA

P: 16506950677

CEO: Elizabeth Homans

Employees: 224

Website: https://lyell.com/